Skip to main content
Midas Edge

FENNEC PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

FENC$10.83+10.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Shareholders’ Deficit

(U.S. dollars and shares in thousands)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Other · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Accumulated · ​ · Comprehensive · ​ · Shareholders’
​ · Number (Note 6) · Amount · Capital · Deficit · Income · Deficit
​​​​​​​​​​​​​​​​​​
Balance at December 31, 2021​26,014​$140,801​$53,214​$(179,486)​$1,243​$15,772
Stock options issued to consultants—​—​133​—​—​133
Stock options issued to employees​—​​—​​4,087​​—​​—​​4,087
Warrants issued in connection with term loan​—​​—​​441​​—​​—​​441
Issuance of securities​—​​—​​(862)​​—​​—​​(862)
Exercise of stock options273​1,790​(216)​—​—​1,574
Restricted stock release74​—​—​—​—​—
Net loss—​—​—​(23,714)​—​(23,714)
Balance at December 31, 202226,361​​142,591​​56,797​​(203,200)​​1,243​​(2,569)
Stock options and restricted share units issued to employees—​—​5,354​—​—​5,354
Exercise of stock options588​1,716​—​—​—​1,716
Restricted stock release​78​​—​​(78)​​—​​—​​(78)
Net loss—​—​—​(16,045)​—​(16,045)
Balance at December 31, 202327,027​$144,307​$62,073​$(219,245)​$1,243​$(11,622)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.